关于共表达Ag85B、Mpt64和Mtb8.4的重组卡介苗的更多疫苗效力研究。
More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.
作者信息
Qie Y Q, Wang J L, Liu W, Shen H, Chen J Z, Zhu B D, Xu Y, Zhang X L, Wang H H
机构信息
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, China.
出版信息
Scand J Immunol. 2009 Apr;69(4):342-50. doi: 10.1111/j.1365-3083.2009.02231.x.
The immunogenicity of the recombinant Bacille Calmette-Guerin: rBCG-Ag85B-Mpt64(190-198)-Mtb8.4 (rBCG-AMM) was evaluated in our previous study. This paper compares the protective efficacy of rBCG-AMM, rBCG-A which overexpresses Ag85B and BCG in C57BL/6 mice. There was no significant difference in proliferation characteristics among rBCG-AMM, rBCG-A and BCG. The growth characteristics of rBCG-AMM in host tissue were identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B-Mpt64(190-198)-Mtb8.4 fusion protein. The protective experiment demonstrated that rBCG-AMM could confer similar or even better protective efficacy against Mycobacterium tuberculosis infection compared with BCG or rBCG-A as evaluated by bacterial organ loads, lung histopathology and net weight gain or loss. The results suggested that the recombinant BCG: rBCG-Ag85B-Mpt64(190-198)-Mtb8.4 is a potential vaccine candidate for further study.
我们之前的研究评估了重组卡介苗rBCG-Ag85B-Mpt64(190 - 198)-Mtb8.4（rBCG-AMM）的免疫原性。本文比较了rBCG-AMM、过表达Ag85B的rBCG-A和卡介苗在C57BL/6小鼠中的保护效力。rBCG-AMM、rBCG-A和卡介苗之间的增殖特性没有显著差异。rBCG-AMM在宿主组织中的生长特性与对照卡介苗相同，这表明增强的保护效力与Ag85B-Mpt64(190 - 198)-Mtb8.4融合蛋白的表达直接相关。保护性实验表明，通过细菌器官负荷、肺组织病理学以及体重净增加或减少评估，与卡介苗或rBCG-A相比，rBCG-AMM对结核分枝杆菌感染可赋予相似甚至更好的保护效力。结果表明，重组卡介苗rBCG-Ag85B-Mpt64(190 - 198)-Mtb8.4是一种有潜力的待进一步研究的疫苗候选物。
Zotero 插件